- Home
- IR vs ARGX Comparison
IR vs ARGX Comparison
Compare IR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IR
- ARGX
- Stock Information
- Founded
- IR 1859
- ARGX 2008
- Country
- IR United States
- ARGX Netherlands
- Employees
- IR N/A
- ARGX N/A
- Industry
- IR Industrial Machinery/Components
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IR Industrials
- ARGX Health Care
- Exchange
- IR Nasdaq
- ARGX Nasdaq
- Market Cap
- IR 40.1B
- ARGX 37.3B
- IPO Year
- IR N/A
- ARGX 2017
- Fundamental
- Price
- IR $94.08
- ARGX $647.39
- Analyst Decision
- IR Buy
- ARGX Strong Buy
- Analyst Count
- IR 13
- ARGX 20
- Target Price
- IR $104.69
- ARGX $653.11
- AVG Volume (30 Days)
- IR 2.2M
- ARGX 250.8K
- Earning Date
- IR 02-13-2025
- ARGX 02-27-2025
- Dividend Yield
- IR 0.09%
- ARGX N/A
- EPS Growth
- IR 9.29
- ARGX N/A
- EPS
- IR 2.05
- ARGX N/A
- Revenue
- IR $7,157,800,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- IR $8.75
- ARGX $70.98
- Revenue Next Year
- IR $6.35
- ARGX $51.22
- P/E Ratio
- IR $45.89
- ARGX N/A
- Revenue Growth
- IR 7.18
- ARGX 85.56
- 52 Week Low
- IR $78.36
- ARGX $349.86
- 52 Week High
- IR $106.03
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- IR 53.40
- ARGX 56.11
- Support Level
- IR $90.29
- ARGX $639.78
- Resistance Level
- IR $91.75
- ARGX $678.21
- Average True Range (ATR)
- IR 1.80
- ARGX 15.44
- MACD
- IR 0.70
- ARGX -0.45
- Stochastic Oscillator
- IR 93.41
- ARGX 52.74
About IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $6.9 billion in revenue in 2023.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.